Last reviewed · How we verify
MK0359
At a glance
| Generic name | MK0359 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016) (PHASE2)
- Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017) (PHASE2)
- A Study of MK0359 in Patients With Chronic Asthma (0359-013) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK0359 CI brief — competitive landscape report
- MK0359 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI